Current status of retroperitoneal lymph node dissection and testicular cancer: When to operate

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Historically, retroperitoneal lymph node dissection (RPLND) has been used in the therapy of both low-stage and high-stage testicular cancer after chemotherapy. As other therapies have developed, the role of RPLND has also evolved. Methods: The authors review the current indications for RPLND in the therapy of testicular cancer. Results: Metastatic testicular cancer can be cured in 50% to 75% of cases by surgical removal using RPLND, depending on the volume of metastasis. In postchemotherapy disease, the surgical removal of teratoma or carcinoma also confers a therapeutic benefit to the patient. Conclusions: The therapeutic capability of RPLND in low-stage testicular cancer is underappreciated. In postchemotherapy disease, this therapeutic capability is retained if the patient has carcinoma or teratoma in the metastatic tumor. In postchemotherapy disease, efforts continue to appropriately select patients preoperatively who have only fibrosis and necrosis in the specimen and therefore do not derive therapeutic benefit from RPLND.

Original languageEnglish
Pages (from-to)277-283
Number of pages7
JournalCancer Control
Volume9
Issue number4
StatePublished - Jul 2002

Fingerprint

Testicular Neoplasms
Lymph Node Excision
Teratoma
Therapeutics
Carcinoma
Fibrosis
Necrosis
Neoplasm Metastasis
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Current status of retroperitoneal lymph node dissection and testicular cancer : When to operate. / Foster, Richard; Bihrle, Richard.

In: Cancer Control, Vol. 9, No. 4, 07.2002, p. 277-283.

Research output: Contribution to journalArticle

@article{50f0296785344eeb9c41d83e989ab380,
title = "Current status of retroperitoneal lymph node dissection and testicular cancer: When to operate",
abstract = "Background: Historically, retroperitoneal lymph node dissection (RPLND) has been used in the therapy of both low-stage and high-stage testicular cancer after chemotherapy. As other therapies have developed, the role of RPLND has also evolved. Methods: The authors review the current indications for RPLND in the therapy of testicular cancer. Results: Metastatic testicular cancer can be cured in 50{\%} to 75{\%} of cases by surgical removal using RPLND, depending on the volume of metastasis. In postchemotherapy disease, the surgical removal of teratoma or carcinoma also confers a therapeutic benefit to the patient. Conclusions: The therapeutic capability of RPLND in low-stage testicular cancer is underappreciated. In postchemotherapy disease, this therapeutic capability is retained if the patient has carcinoma or teratoma in the metastatic tumor. In postchemotherapy disease, efforts continue to appropriately select patients preoperatively who have only fibrosis and necrosis in the specimen and therefore do not derive therapeutic benefit from RPLND.",
author = "Richard Foster and Richard Bihrle",
year = "2002",
month = "7",
language = "English",
volume = "9",
pages = "277--283",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "4",

}

TY - JOUR

T1 - Current status of retroperitoneal lymph node dissection and testicular cancer

T2 - When to operate

AU - Foster, Richard

AU - Bihrle, Richard

PY - 2002/7

Y1 - 2002/7

N2 - Background: Historically, retroperitoneal lymph node dissection (RPLND) has been used in the therapy of both low-stage and high-stage testicular cancer after chemotherapy. As other therapies have developed, the role of RPLND has also evolved. Methods: The authors review the current indications for RPLND in the therapy of testicular cancer. Results: Metastatic testicular cancer can be cured in 50% to 75% of cases by surgical removal using RPLND, depending on the volume of metastasis. In postchemotherapy disease, the surgical removal of teratoma or carcinoma also confers a therapeutic benefit to the patient. Conclusions: The therapeutic capability of RPLND in low-stage testicular cancer is underappreciated. In postchemotherapy disease, this therapeutic capability is retained if the patient has carcinoma or teratoma in the metastatic tumor. In postchemotherapy disease, efforts continue to appropriately select patients preoperatively who have only fibrosis and necrosis in the specimen and therefore do not derive therapeutic benefit from RPLND.

AB - Background: Historically, retroperitoneal lymph node dissection (RPLND) has been used in the therapy of both low-stage and high-stage testicular cancer after chemotherapy. As other therapies have developed, the role of RPLND has also evolved. Methods: The authors review the current indications for RPLND in the therapy of testicular cancer. Results: Metastatic testicular cancer can be cured in 50% to 75% of cases by surgical removal using RPLND, depending on the volume of metastasis. In postchemotherapy disease, the surgical removal of teratoma or carcinoma also confers a therapeutic benefit to the patient. Conclusions: The therapeutic capability of RPLND in low-stage testicular cancer is underappreciated. In postchemotherapy disease, this therapeutic capability is retained if the patient has carcinoma or teratoma in the metastatic tumor. In postchemotherapy disease, efforts continue to appropriately select patients preoperatively who have only fibrosis and necrosis in the specimen and therefore do not derive therapeutic benefit from RPLND.

UR - http://www.scopus.com/inward/record.url?scp=0036638977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036638977&partnerID=8YFLogxK

M3 - Article

C2 - 12228753

AN - SCOPUS:0036638977

VL - 9

SP - 277

EP - 283

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 4

ER -